share_log

Capital One Upgrades Outlook Therapeutics to Overweight, Announces $5 Price Target

Capital One Upgrades Outlook Therapeutics to Overweight, Announces $5 Price Target

Capital One將Outlook Therapeutics上調至增持,宣佈5美元的
Benzinga ·  2023/12/27 08:58

Capital One analyst Zegbeh Jallah upgrades Outlook Therapeutics (NASDAQ:OTLK) from Equal-Weight to Overweight and announces $5 price target.

Capital One分析師澤格貝·賈拉將Outlook Therapeutics(納斯達克股票代碼:OTLK)從等重上調至增持,並宣佈了5美元的目標股價。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論